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Book Reviews
Advances in Enzyme-Regulation. Vol. 31
Edited by G. Weber, Oxford: Pergamon Press, 1991, 496 pp.
£200.00.
The title of this multiauthor volume is a little misleading.
The contributions are based on the proceedings of the 31st
annual symposium on the Regulation of Enzyme Activity
and Synthesis in Normal and Neoplastic Cells. This was held
in Indianopolis in October 1990 so the material is fairly
topical. There are 24 papers covering a wide range of sub-
jects. Not all of these have much connection with enzyme
regulation, but a number will be of interest to cancer re-
searchers. In particular there is quite a lot here for those
interested in anticancer drug development. Space precludes
mentioning all of the contributions, but some of these are
discussed to give a flavour of the volume.
The chapter by Jackman et al. shows how an integration
of enzymology with other investigations had led to the
clinical evaluation of improved folate-based thymidylate
synthetase inhibitors. Harrap and colleagues describe their
progress in developing orally active platinum coordination
complexes which also circumvent some forms of cisplatin
resistance. The rationale for the combined inhibition of de
novo and salvage pathways for purine and pyrimidine meta-
bolism is reviewed by Weber et al.
I personally enjoyed the updates on the multiple forms of
protein kinase C including their possible roles in cancer cell
signalling (Ohno et al.) and on the regulation of the gluta-
thione transferase P gene (Muramatsu et al.) and the
CYPIAJ gene which encodes the cytochrome P450 lAl (Lus-
ska et al.).
The review by Estabrook et al. gives some nice samples of
the value of expressing cloned P450 genes in bacterial, yeast
or mammalian host cells. Schwab provides a critical piece on
N-myc and Capitani and colleagues discuss their data on
nuclear inositol lipids in the context of the growing realisa-
tion that the isoitol lipid - protein kinase C signalling path-
ways may exist within the nucleus itself. A major problem
with both antibodies and antisense oligonucleotides as thera-
peutic agents concerns the delivery of these large molecules
and Severin et al. show how 'hydrophobisation' with fatty
acid residues may improve their antiviral activity.
Inevitably in this type of production there are stylistic
disparities between contributions, some being pure reviews,
but most being more formal presentations of in-house data.
Also inevitably, most of the material has appeared or will
appear elsewhere in the literature. I found some of 'Session'
titles rather puzzling. The book is also expensive. However,
the articles are readable and interesting and the quality ofthe
editing and production is excellent. There should be some-
thing in this pot pourri to interest most cancer researchers
(certainly most cancer pharmacologists). I for one found it
worth perusing, not least for the charming and informative
personal anecdote from Nobel Laureate George Hitchings
which concludes the book.
P. Workman
Immunodiagnosis of Cancer (second edition)
Edited by R.B. Herberman & D.W. Mercer, New York:
Marcel Dekker Inc., 1990, 712 pp. $150 (USA & Canada),
$180.00 (Others).
This is the second edition of Immunodiagnosis ofCancer, the
53rd publication in an immunology series going back more
than a decade. Since the previous edition was published in
1979, there has been a vast expansion in immunological
techniques including the widespread availability and use of
monoclonal antibodies. In addition, the increasing sensitivity
and specificity of assay procedures has lead to much greater
complexity in this field. In this edition, the editors aim to
acquaint the reader with both the theoretical and practical
aspects ofimmunodiagnosis and its relevance in cancer. They
cover experimental design, methodology, organ site-assoc-
iated tumour markers and non organ site-restricted tumour
markers.
The standard of contributions in this book is generally
high. There is a concise overview of the value of serum
markers in a number of common tumour types emphasising
the uses (and limitations) of a panel approach. The meth-
odology section reviews the majority of useful techniques in
detail; as well as monoclonal antibodies (production and
usage) and a full discussion of immunoassay technology,
molecular biological techniques and flow cytometry are also
covered. The organ site-associated tumour markers are re-
viewed in seventeen chapters, each devoted to a particular
tumour site or type; much of this gives us interesting insight
into the biology of these tumours. The immunophenotypic
classification of lymphoma and leukaemia using a few crucial
commercially available immunocytochemical markers, and
the use of serum markers to assess response of certain
tumours to treatment, are of particular practical value. The
fourth section deals with topics such as immunoglobulins,
acute phase proteins, immune complexes, fibronectin, serum
isoenzymes, mucin glycoproteins and placental proteins. Each
of these chapters gives an up to date statement of present
knowledge with an extensive literature review.
The text is liberally sprinkled with high quality line draw-
ings and tables where appropriate. The book highlights those
areas in which there is uncertainty and suggests a wide area
of potential expansion in the future. It must be regarded as a
key reference text for both research workers and clinicians
with an interest in tumour pathology and immunology.
J.B. Schofield
N.A. Wright
Non-Melanocytic Tumors of the Skin
Atlas of Tumor Pathology, Third Series, No. 1.
G.F. Murphy & D.E. Elder, Washington: AFIP, 1991,
287pp. $45.00.
Melanocytic Tumors of the Skin
Atlas of Tumor Pathology, Third Series, No. 2.
D.E. Elder & G.F. Murphy, Washington: AFIP, 1991,
216pp. $45.00
Surgical pathologists sometimes feel regarded by their clinical
colleagues as a modern manifestation of the oracle of ancient
times. Instead of sacrificing an animal and then examining its
entrails to foretell the future we now remove part of the
patient instead and then expect the pathologist to provide
detailed prognostic information on the biopsy material that is
submitted to the laboratory. Of course the ancient Greeks
did not go to any old oracle, but would travel to Delphi for
the best available opinion. In present times it is not always
appreciated that the choice of surgical pathologist may be as
important as the choice of oracle in those days, and can
easily be as important as the choice of surgeon or oncologist
in determining the changes of success in the diagnosis and
management of patients with tumours. The experience of the
British Melanoma Club over the last decade has shown
clearly that in the field of pigmented lesions there is con-
siderable interobserver variation, with universal agreement on
diagnosis hard to find amongst a group of motivated and